Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 3 3Phase 1 3Phase EARLY_PHASE1 1Phase 4 1Phase 1/2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 624pembrolizumab 500Paclitaxel 456Gemcitabine 438Carboplatin 435Cisplatin 418Radiotherapy 380fludarabine 365Nivolumab 340Docetaxel 277Bevacizumab 276Irinotecan 257Magnetic Resonance Spectroscopy 242Fluorouracil 228Dexamethasone 225Specimen Handling 221Capecitabine 218Rituximab 205Cytarabine 201Oxaliplatin 200Ipilimumab 199Temozolomide 197Biopsy 196fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 173Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Radium-223 × Clear all
NCT04109729 2026-03-02

Rad2Nivo

University of Utah

Phase 1 Active not recruiting
39 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT03737370 2025-10-07

Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer

Tufts Medical Center

Phase 1 Completed
43 enrolled
Genitourinary

Prostatic Neoplasms

NCT02406521 2020-03-04

Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets

Dana-Farber Cancer Institute

Phase 1 Completed
30 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡